Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite

Paula B. Caffrey, Gerald Frenkel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background/Aim: We have been exploring a prevention approach to the problem of drug resistance which develops during ovarian cancer chemotherapy. We have previously described an in vivo model of the development of resistance to the chemotherapy drug cisplatin in xenografts, and the prevention of this resistance by selenium compounds. However, a different platinum-based drug, carboplatin, is frequently utilized in ovarian cancer treatment. The aim of the present study was to design a model for the induction of resistance by carboplatin in vivo. Materials and Methods: Tumors were initiated in immunodeficient mice by subcutaneous inoculation of A2780 human ovarian tumor cells. The sensitivity of the resulting tumors to therapy was determined by measuring the effect on tumor growth of a single intraperitoneal (i.p.) treatment with a high dose of carboplatin. Results: The growth of control tumors was completely (although temporarily) stopped by this treatment; however, a single pre-treatment with a low i.p. dose of carboplatin resulted in the rapid development of resistance to carboplatin, and cross-resistance to cisplatin. Pre-treatment with selenite in addition to carboplatin prevented the induction of resistance. When cells from these pre-treated tumors were transplanted to new animals, the derivative tumors retained the sensitive or resistant phenotype of their tumor of origin. Conclusion: Selenite can prevent the induction of resistance by carboplatin in human ovarian tumors, and thus may offer an approach to extending the long-term efficacy of platinum chemotherapy.

Original languageEnglish (US)
Pages (from-to)4249-4254
Number of pages6
JournalAnticancer Research
Volume33
Issue number10
StatePublished - Oct 1 2013

Fingerprint

Selenious Acid
Carboplatin
Heterografts
Neoplasms
Platinum
Drug Therapy
Ovarian Neoplasms
Cisplatin
Therapeutics
Selenium Compounds
Growth
Drug Resistance
Pharmaceutical Preparations
Phenotype

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • Carboplatin
  • Drug resistance
  • Ovarian cancer
  • Selenite
  • Xenografts

Cite this

@article{543b1c76583d4f3e80c7099c18fff570,
title = "Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite",
abstract = "Background/Aim: We have been exploring a prevention approach to the problem of drug resistance which develops during ovarian cancer chemotherapy. We have previously described an in vivo model of the development of resistance to the chemotherapy drug cisplatin in xenografts, and the prevention of this resistance by selenium compounds. However, a different platinum-based drug, carboplatin, is frequently utilized in ovarian cancer treatment. The aim of the present study was to design a model for the induction of resistance by carboplatin in vivo. Materials and Methods: Tumors were initiated in immunodeficient mice by subcutaneous inoculation of A2780 human ovarian tumor cells. The sensitivity of the resulting tumors to therapy was determined by measuring the effect on tumor growth of a single intraperitoneal (i.p.) treatment with a high dose of carboplatin. Results: The growth of control tumors was completely (although temporarily) stopped by this treatment; however, a single pre-treatment with a low i.p. dose of carboplatin resulted in the rapid development of resistance to carboplatin, and cross-resistance to cisplatin. Pre-treatment with selenite in addition to carboplatin prevented the induction of resistance. When cells from these pre-treated tumors were transplanted to new animals, the derivative tumors retained the sensitive or resistant phenotype of their tumor of origin. Conclusion: Selenite can prevent the induction of resistance by carboplatin in human ovarian tumors, and thus may offer an approach to extending the long-term efficacy of platinum chemotherapy.",
keywords = "Carboplatin, Drug resistance, Ovarian cancer, Selenite, Xenografts",
author = "Caffrey, {Paula B.} and Gerald Frenkel",
year = "2013",
month = "10",
day = "1",
language = "English (US)",
volume = "33",
pages = "4249--4254",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite. / Caffrey, Paula B.; Frenkel, Gerald.

In: Anticancer Research, Vol. 33, No. 10, 01.10.2013, p. 4249-4254.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite

AU - Caffrey, Paula B.

AU - Frenkel, Gerald

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background/Aim: We have been exploring a prevention approach to the problem of drug resistance which develops during ovarian cancer chemotherapy. We have previously described an in vivo model of the development of resistance to the chemotherapy drug cisplatin in xenografts, and the prevention of this resistance by selenium compounds. However, a different platinum-based drug, carboplatin, is frequently utilized in ovarian cancer treatment. The aim of the present study was to design a model for the induction of resistance by carboplatin in vivo. Materials and Methods: Tumors were initiated in immunodeficient mice by subcutaneous inoculation of A2780 human ovarian tumor cells. The sensitivity of the resulting tumors to therapy was determined by measuring the effect on tumor growth of a single intraperitoneal (i.p.) treatment with a high dose of carboplatin. Results: The growth of control tumors was completely (although temporarily) stopped by this treatment; however, a single pre-treatment with a low i.p. dose of carboplatin resulted in the rapid development of resistance to carboplatin, and cross-resistance to cisplatin. Pre-treatment with selenite in addition to carboplatin prevented the induction of resistance. When cells from these pre-treated tumors were transplanted to new animals, the derivative tumors retained the sensitive or resistant phenotype of their tumor of origin. Conclusion: Selenite can prevent the induction of resistance by carboplatin in human ovarian tumors, and thus may offer an approach to extending the long-term efficacy of platinum chemotherapy.

AB - Background/Aim: We have been exploring a prevention approach to the problem of drug resistance which develops during ovarian cancer chemotherapy. We have previously described an in vivo model of the development of resistance to the chemotherapy drug cisplatin in xenografts, and the prevention of this resistance by selenium compounds. However, a different platinum-based drug, carboplatin, is frequently utilized in ovarian cancer treatment. The aim of the present study was to design a model for the induction of resistance by carboplatin in vivo. Materials and Methods: Tumors were initiated in immunodeficient mice by subcutaneous inoculation of A2780 human ovarian tumor cells. The sensitivity of the resulting tumors to therapy was determined by measuring the effect on tumor growth of a single intraperitoneal (i.p.) treatment with a high dose of carboplatin. Results: The growth of control tumors was completely (although temporarily) stopped by this treatment; however, a single pre-treatment with a low i.p. dose of carboplatin resulted in the rapid development of resistance to carboplatin, and cross-resistance to cisplatin. Pre-treatment with selenite in addition to carboplatin prevented the induction of resistance. When cells from these pre-treated tumors were transplanted to new animals, the derivative tumors retained the sensitive or resistant phenotype of their tumor of origin. Conclusion: Selenite can prevent the induction of resistance by carboplatin in human ovarian tumors, and thus may offer an approach to extending the long-term efficacy of platinum chemotherapy.

KW - Carboplatin

KW - Drug resistance

KW - Ovarian cancer

KW - Selenite

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=84891368150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891368150&partnerID=8YFLogxK

M3 - Article

C2 - 24122988

AN - SCOPUS:84891368150

VL - 33

SP - 4249

EP - 4254

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -